Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2015

Open Access 01-05-2015 | Article

Low prevalence of Blastocystis sp. in active ulcerative colitis patients

Authors: N. G. Rossen, A. Bart, N. Verhaar, E. van Nood, R. Kootte, P. F. de Groot, G. R. D’Haens, C. Y. Ponsioen, T. van Gool

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2015

Login to get access

Abstract

Ulcerative colitis (UC) is thought to originate from a disbalance in the interplay between the gut microbiota and the innate and adaptive immune system. Apart from the bacterial microbiota, there might be other organisms, such as parasites or viruses, that could play a role in the aetiology of UC. The primary objective of this study was to compare the prevalence of Blastocystis sp. in a cohort of patients with active UC and compare that to the prevalence in healthy controls. We studied patients with active UC confirmed by endoscopy included in a randomised prospective trial on the faecal transplantation for UC. A cohort of healthy subjects who served as donors in randomised trials on faecal transplantation were controls. Healthy subjects did not have gastrointestinal symptoms and were extensively screened for infectious diseases by a screenings questionnaire, extensive serologic assessment for viruses and stool analysis. Potential parasitic infections such as Blastocystis were diagnosed with the triple faeces test (TFT). The prevalence of Blastocystis sp. were compared between groups by Chi-square testing. A total of 168 subjects were included, of whom 45 had active UC [median age 39.0 years, interquartile range (IQR) 32.5–49.0, 49 % male] and 123 were healthy subjects (median age 27 years, IQR 22.0–37.0, 54 % male). Blastocystis sp. was present in the faeces of 40/123 (32.5 %) healthy subjects and 6/45 (13.3 %) UC patients (p = 0.014). Infection with Blastocystis is significantly less frequent in UC patients as compared to healthy controls.
Literature
3.
go back to reference Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17:179–184. doi:10.1002/ibd.21339 CrossRefPubMed Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17:179–184. doi:10.​1002/​ibd.​21339 CrossRefPubMed
4.
go back to reference Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V et al (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275–1283. doi:10.1136/gutjnl-2013-304833 CrossRefPubMed Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V et al (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275–1283. doi:10.​1136/​gutjnl-2013-304833 CrossRefPubMed
6.
go back to reference Horiki N, Maruyama M, Fujita Y, Yonekura T, Minato S, Kaneda Y (1997) Epidemiologic survey of Blastocystis hominis infection in Japan. Am J Trop Med Hyg 56:370–374PubMed Horiki N, Maruyama M, Fujita Y, Yonekura T, Minato S, Kaneda Y (1997) Epidemiologic survey of Blastocystis hominis infection in Japan. Am J Trop Med Hyg 56:370–374PubMed
8.
10.
go back to reference Yamamoto-Furusho JK, Torijano-Carrera E (2010) Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course. Digestion 82:18–23. doi:10.1159/000273871 CrossRefPubMed Yamamoto-Furusho JK, Torijano-Carrera E (2010) Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course. Digestion 82:18–23. doi:10.​1159/​000273871 CrossRefPubMed
11.
go back to reference Nagler J, Brown M, Soave R (1993) Blastocystis hominis in inflammatory bowel disease. J Clin Gastroenterol 16:109–112CrossRefPubMed Nagler J, Brown M, Soave R (1993) Blastocystis hominis in inflammatory bowel disease. J Clin Gastroenterol 16:109–112CrossRefPubMed
12.
go back to reference Krogsgaard LR, Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P (2014) The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case–control study. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2014.07.065 Krogsgaard LR, Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P (2014) The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case–control study. Clin Gastroenterol Hepatol. doi: 10.​1016/​j.​cgh.​2014.​07.​065
15.
16.
17.
go back to reference van Gool T, Weijts R, Lommerse E, Mank TG (2003) Triple Faeces Test: an effective tool for detection of intestinal parasites in routine clinical practice. Eur J Clin Microbiol Infect Dis 22:284–290. doi:10.1007/s10096-003-0919-1 PubMed van Gool T, Weijts R, Lommerse E, Mank TG (2003) Triple Faeces Test: an effective tool for detection of intestinal parasites in routine clinical practice. Eur J Clin Microbiol Infect Dis 22:284–290. doi:10.​1007/​s10096-003-0919-1 PubMed
19.
go back to reference Scanlan PD, Stensvold CR, Rajilić-Stojanović M, Heilig HGHJ, De Vos WM, O’Toole PW et al (2014) The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. FEMS Microbiol Ecol 90:326–330. doi:10.1111/1574-6941.12396 CrossRefPubMed Scanlan PD, Stensvold CR, Rajilić-Stojanović M, Heilig HGHJ, De Vos WM, O’Toole PW et al (2014) The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. FEMS Microbiol Ecol 90:326–330. doi:10.​1111/​1574-6941.​12396 CrossRefPubMed
20.
go back to reference Yoshikawa H, Dogruman-Al F, Turk S, Kustimur S, Balaban N, Sultan N (2011) Evaluation of DNA extraction kits for molecular diagnosis of human Blastocystis subtypes from fecal samples. Parasitol Res 109:1045–1050. doi:10.1007/s00436-011-2342-3 CrossRefPubMed Yoshikawa H, Dogruman-Al F, Turk S, Kustimur S, Balaban N, Sultan N (2011) Evaluation of DNA extraction kits for molecular diagnosis of human Blastocystis subtypes from fecal samples. Parasitol Res 109:1045–1050. doi:10.​1007/​s00436-011-2342-3 CrossRefPubMed
22.
go back to reference Haider SS, Baqai R, Qureshi FM, Boorom K (2012) Blastocystis spp., Cryptosporidium spp., and Entamoeba histolytica exhibit similar symptomatic and epidemiological patterns in healthcare-seeking patients in Karachi. Parasitol Res 111:1357–1368. doi:10.1007/s00436-012-2972-0 CrossRefPubMed Haider SS, Baqai R, Qureshi FM, Boorom K (2012) Blastocystis spp., Cryptosporidium spp., and Entamoeba histolytica exhibit similar symptomatic and epidemiological patterns in healthcare-seeking patients in Karachi. Parasitol Res 111:1357–1368. doi:10.​1007/​s00436-012-2972-0 CrossRefPubMed
23.
24.
go back to reference Fletcher S, Caprarelli G, Merif J, Andresen D, Van Hal S, Stark D et al (2014) Epidemiology and geographical distribution of enteric protozoan infections in Sydney, Australia. J Public Health Res 3:298CrossRefPubMedCentralPubMed Fletcher S, Caprarelli G, Merif J, Andresen D, Van Hal S, Stark D et al (2014) Epidemiology and geographical distribution of enteric protozoan infections in Sydney, Australia. J Public Health Res 3:298CrossRefPubMedCentralPubMed
25.
go back to reference Petersen AM, Stensvold CR, Mirsepasi H, Engberg J, Friis-Møller A, Porsbo LJ et al (2013) Active ulcerative colitis associated with low prevalence of Blastocystis and Dientamoeba fragilis infection. Scand J Gastroenterol 48:638–639. doi:10.3109/00365521.2013.780094 CrossRefPubMed Petersen AM, Stensvold CR, Mirsepasi H, Engberg J, Friis-Møller A, Porsbo LJ et al (2013) Active ulcerative colitis associated with low prevalence of Blastocystis and Dientamoeba fragilis infection. Scand J Gastroenterol 48:638–639. doi:10.​3109/​00365521.​2013.​780094 CrossRefPubMed
27.
go back to reference Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66:5224–5231PubMedCentralPubMed Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66:5224–5231PubMedCentralPubMed
31.
go back to reference Udkow MP, Markell EK (1993) Blastocystis hominis: prevalence in asymptomatic versus symptomatic hosts. J Infect Dis 168:242–244CrossRefPubMed Udkow MP, Markell EK (1993) Blastocystis hominis: prevalence in asymptomatic versus symptomatic hosts. J Infect Dis 168:242–244CrossRefPubMed
Metadata
Title
Low prevalence of Blastocystis sp. in active ulcerative colitis patients
Authors
N. G. Rossen
A. Bart
N. Verhaar
E. van Nood
R. Kootte
P. F. de Groot
G. R. D’Haens
C. Y. Ponsioen
T. van Gool
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2312-2

Other articles of this Issue 5/2015

European Journal of Clinical Microbiology & Infectious Diseases 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine